RIZE ONCOLOGY INC.RRIZE ONCOLOGY INC.

RIZE ONCOLOGY INC.

0.120CADR
−0.030−20.00%
At close at Jan 22, 22:04 GMT
CAD
No trades
See on Supercharts

RIZE fundamentals

Key facts

Market capitalization‪4.11 M‬CAD
Basic EPS (TTM)−0.03CAD
Founded2018
CEORoland Boivin
About

Rize Oncology, Inc. is a genetic medicines company, which engages in the creation of gene editing therapies based on the GeneTether platform. The company was founded by Daren Graham, William J. Garner, and R. Geoffrey Sargent on February 12, 2018 and is headquartered in Kelowna, Canada.

Ownership
‪‪34.25 M‬‬
Free Float shares
‪‪34.25 M‬‬ (100%)
Free Float shares
‪‪34.25 M‬‬ (100%)
Capital structure
Market cap
‪‪4.11 M‬‬
Cash & equivalents
‪‪1.31 M‬‬
Enterprise value
‪‪2.80 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪4.11 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24

Growth and Profitability

Company’s recent performance and margins

Performance
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−440.00 K‬‬
‪‪−330.00 K‬‬
‪‪−220.00 K‬‬
‪‪−110.00 K‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−200.00 K‬‬
‪‪−150.00 K‬‬
‪‪−100.00 K‬‬
‪‪−50.00 K‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−200.00 K‬‬
‪‪−150.00 K‬‬
‪‪−100.00 K‬‬
‪‪−50.00 K‬‬
‪0.00‬

Dividends

Dividend yield, history and sustainability

RIZE does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−700.00 K‬‬
‪0.00‬
‪‪700.00 K‬‬
‪‪1.40 M‬‬
‪‪2.10 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪400.00 K‬‬
‪‪800.00 K‬‬
‪‪1.20 M‬‬
‪‪1.60 M‬‬
Assets
Liabilities